Nuvation BioNUVB +5.17%33 Pretax Margin % is 6.48% as of Mar. 2026. GuruFocus rates NUVB with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 942 Biotechnology companies, Nuvation Bio ranks worse than 51.49% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Nuvation Bio's Pre-Tax Income for the
three
months ended in Mar. 2026 was $5.4 Mil. Nuvation Bio's Revenue for the
three
months ended in Mar. 2026 was $83.2 Mil. Therefore, Nuvation Bio's pretax margin for the quarter that ended in Mar. 2026 was 6.48%.
The historical rank and industry rank for Nuvation Bio's Pretax Margin % or its related term are showing as below:
NUVB'
s Pretax Margin % Range Over the Past 10 Years
Min: -7213.76 Med: -3769.54 Max: -102.06
Current: -102.06
NUVB's Pretax Margin % is ranked worse than 51.49% of 942
companies
in the Biotechnology industry
Industry Median: -90.5
vs NUVB: -102.06
Nuvation Bio (NYSE:NUVB) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Nuvation Bio Pretax Margin % Related Terms
Nuvation Bio Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Nuvation Bio's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUVB vs VRDN, STOK, ATAI: Pretax Margin % Comparison
For the Biotechnology subindustry, Nuvation Bio's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NUVB) has a Pretax Margin % of 6.48% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Nuvation Bio and its competitors. According to the industry distribution chart, Nuvation Bio ranks #485 out of 942 companies in the Biotechnology industry, placing it in the top 51.5%.
Is Nuvation Bio's Pretax Margin % too high?
Nuvation Bio's current Pretax Margin % is 6.48%. Based on the distribution chart, Nuvation Bio ranks #485 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nuvation Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's Pretax Margin % compare to VRDN and STOK?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #485 out of 942 companies for Pretax Margin %. This places Nuvation Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Nuvation Bio and its competitors. Nuvation Bio's current Pretax Margin % is 6.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current Pretax Margin % of 6.48%. The current Pretax Margin % is 6.48%. Nuvation Bio's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current Pretax Margin % is 6.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
33GF Score
Get the complete analysis for NUVB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUVB has been successfully added to your 
